Grace Therapeutics, Inc. Common Stock (GRCE) is a publicly traded Healthcare sector company. As of May 21, 2026, GRCE trades at $2.21 with a market cap of $33.58M and a P/E ratio of -2.75. GRCE moved +1.63% today. Year to date, GRCE is -39.94%; over the trailing twelve months it is -26.54%. Its 52-week range spans $1.75 to $5.18. Analyst consensus is buy with an average price target of $6.00. Rallies surfaces GRCE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Grace Therapeutics, Inc. Common Stock (GRCE) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. GRCE moved +1.63% today. Analyst consensus is buy.
| Metric | Value |
|---|---|
| Price | $2.21 |
| Market Cap | $33.58M |
| P/E Ratio | -2.75 |
| EPS | $-0.79 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.18 |
| 52-Week Low | $1.75 |
| Volume | 4 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-9.57M |
| Gross Margin | 0.00% |
2 analysts cover GRCE: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.00.